After decades of stalled progress, a new wave of clinical research involving psychedelic compounds shows promising results for treating depression, addiction, PTSD, and other mental health conditions.

A multinational clinical trial of MDMA-assisted treatment for PTSD is currently underway in Canada, the US, and Israel. Sponsored by the Multidisciplinary Association for Psychedelic Studies (MAPS), this research holds the potential to make MDMA available to the public as a medicine for use in conjunction with psychotherapy by 2023, revolutionizing treatment for one of humanity’s most debilitating forms of suffering.

Mindspace is committed to exploring the potential of this exciting new field and alongside partners in the USA and Canada is offering continuing education training programs for health care professionals interested in doing the same.

Psychedelics 101 & 102 for Clinicians is 2-day training offered by psychologists Ingmar Gorman and Elizabeth Nielson is designed for clinicians and healthcare providers who want to learn more about current psychedelic research and clinical practice, including how to work with patients who have a history of psychedelic use or have expressed an interest in using psychedelics. This is the first time this program has been offered in Canada.

Click a program below to learn more.

Upcoming Psychedelic Psychotherapy Programs